Forecasting disease progression
About us
We are an AI-driven precision medicine company developing a multimodal prognostic platform to forecast disease progression in age-related disorders. Our forecasts provide new tools to physicians for improved patient care and to pharmaceutical companies for faster drug development. Our current applications are in Alzheimer's disease.
Foresight™ - Our Predictive Platform
Multimodal
Our platform can leverage multiple sources of data (imaging, genetic, phenotypic, molecular and clinical variables) to better characterize individuals.
High precision targeting
We are able to rapidly and precisely target subgroups of interest in large, heterogeneous populations.
Highly actionable insights
Our digital biomarkers are highly specific and thoroughly validated, making them ready for action in any clinical setting.
To learn more, visit our Publications page!
Latest News
Perceiv AI Achieves HIPAA Compliance, Reinforcing Commitment to Data Security and Privacy
November 28, 2023 | Montreal, Canada | Press release
New results presented at CTAD 2023 "Reducing screen failure rates due to biomarker cut-offs in early Alzheimer's disease trials using a prognostic model"
October 24, 2023 | Clinical Trials on Alzheimer's Disease conference (CTAD) | Poster
Perceiv AI Joins Johnson & Johnson Innovation–JLABS Global Network to Accelerate Precision Medicine Platform Development
June 21, 2023 | Toronto, Canada | Annoucement
Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort
January 17, 2023 | Boston, USA | Annoucement
Perceiv AI announces an investment of $1.5M from strategic and institutional investors to support the expansion of its prognostic platform Foresight(TM).
December 8, 2022 | Montréal, Canada | Press release
Perceiv AI today announced the closing of an investment of $1.5M. Perceiv AI is a precision medicine company optimizing and de-risking clinical trials and enabling physicians to make a timely diagnosis of degenerative brain disorders by forecasting disease evolution.
The round was composed of strategic and institutional investors from Canada and the US, including CABHI (Centre for Aging + Brain Health Innovation), Plug and Play Ventures, Boreal Ventures, IKJ Capital, Red Abbey Labs, Investissement Québec, as a representative of the government of Quebec, as well as angel investors. "We are very excited to move forward to the next phase of our growth with the support of these strategically important investors," said Dr. Christian Dansereau, CEO of Perceiv AI.
The funds will be used to expand the Foresight platform, Perceiv AI's proprietary AI/ML-driven prognostic platform that predicts disease progression. The company aims to add other key resources by bringing additional talent to the team to advance its commercial and scientific activities and strengthen its regulatory effort.
Perceiv AI Leverages Big Data and Artificial Intelligence to Predict Disease Progression and Make Clinical Trials More Effective
December 2, 2022 | Montréal, Canada | Press release
Find all our past news and announcements in our Newsroom!
Meet our Team
Christian Dansereau, Ph.D.
CEO & Founder
César Laurent, Ph.D.
CTO & Founder
Angela Tam, Ph.D.
Senior Scientist
Adrián Noriega de la Colina, M.D., Ph.D.
Clinical and Regulatory Lead
Maxime Jacques, M.A.Sc
Platform
Software Engineer
Meet our Advisors
Yoshua Bengio, Ph.D.
Full Professor at Université de Montréal,
Founder and Scientific Director of Mila,
Scientific Director of IVADO
Serge Gauthier, M.D.
Full Professor at McGill University,
Director of the Alzheimer Disease and Related Disorders Research Unit, Douglas Research Centre
Betsabeh Madani Hermann, M.B.A.
Healthcare executive & investor,
VP strategy and BD
Investors
Partners & Collaborators
Supported by
